The shares of Altimmune and Pubmatic: Your path to your first million? A financial expert will give you insight.

The shares of Altimmune and Pubmatic: Your path to your first million? A financial expert will give you insight.

According to a report by www.aktienwelt360.de,

A recent report highlights two unknown stocks that have the potential to help investors on their way to making their first million. These are Altimmune (WKN: A2N5Z6) and Pubmatic (WKN: A2QJL6). Both stocks are small, dynamic growth stocks with higher risk, but also significant opportunity potential.

Altimmune focuses on the treatment of obesity and could be about to launch its product pemvidutide on the market in the medium term. The share price rose from 2.18 euros to 6.15 euros in a month after positive study data was published. The market capitalization is currently $350 million, but a successful launch could give the company a significant share of the obesity treatment market.

Pubmatic, a digital advertising specialist, also has a lot of potential to compete in a market with a forecast growth rate of 7.2% per year. Although revenue fell slightly in the third quarter, Pubmatic is already profitable and has a market cap of $868 million. In the long term, the company could benefit from the growing importance of digital advertising.

Both stocks offer opportunities but also risks due to their small size and growth phase. Investors should therefore carefully consider whether they want to invest in these stocks. The figures and forecasts mentioned should serve as a guide for making an informed decision.